Business
Aligos Therapeutics Announces Six Preclinical Presentations at the 2025 International HBV Meeting
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced six presentations, including three oral presentations, at the 2025 International HBV Meeting, being held September 8 – 12, 2025 in Berlin, Germany. The company and its collaborators’ commitment to advancing next-generation therapies fo
About this update from Aligos Therapeutics, Inc.
[{"type":"image","alt":"Aligos Therapeutics","displaySize":"","headline":null,"caption":"Aligos Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":150,"height":50,"url":"https://media.zenfs.com/en/globenewswire.com/209c9435fdfab4fa4ff642c123fac955"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/L8133ghONMF7WN.yZV6tsw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTcwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/209c9435fdfab4fa4ff642c123fac955","width":150,"height":50}},"lazy":false},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced six presentations, including three oral presentations, at the 2025 International HBV Meeting, being held September 8 – 12, 2025 in Berlin, Germany.","length":412,"tagName":"p"},{"type":"text","content":"The company and its collaborators’ commitment to advancing next-generation therapies for liver and viral diseases is reflected in these presentations, with topics spanning novel approaches, molecular strategies, insights into the mechanisms of action of ALG-000184, as well as a new strategy to potentially cure hepatitis delta virus (HDV) infection utilizing a proprietary antisense oligonucleotide (ASO) approach.","length":415,"tagName":"p"},{"type":"text","content":"“We are pleased to present six preclinical presentations at the International HBV Meeting, that showcase our continued innovation in liver and viral diseases. With the Phase 2 B-Supreme study progressing nicely, we are pleased to present, for the first time, the direct effects of ALG-000184 in reducing HBV cccDNA in a preclinical setting. These data help corroborate the clinical observations of HBV antigen reductions seen in patients with chronic HBV infection treated with ALG-000184 monotherapy to date and are a direct indication that ALG-000184 can invoke the secondary mechanism of CAM-Es,” stated Lawrence Blatt, PhD, MBA, Chairman, President, and Chief Executive Officer of Aligos Therapeutics. “While we remain committed to the continued development of our best/first-in-class CAM-E ALG-000184 for chronic HBV infection, we are pleased to broaden our pipeline with the presentation of our di...